Jiangsu Hengrui Pharmaceuticals Co Ltd

Jiangsu Hengrui Pharmaceuticals launches a self‑funded A‑share buy‑back (Aug 2025‑Aug 2026) and names Zhu Guoxin senior VP, boosting shareholder value and leadership stability.

Hengrui Pharmaceuticals shares rise modestly as the company focuses on high‑margin oncology pipelines, regulatory‑accelerated approvals, and sustainable growth in China’s pharma market.

Jiangsu Hengrui’s latest corporate and clinical updates: a Phase‑II injectable for membranous nephropathy, a new breast‑cancer partnership, and 2025 lock‑up expiry insights for investors and clinicians.

Jiangsu Hengrui Pharmaceuticals’ Q3 2023 report shows steady revenue & profit growth, a robust oncology pipeline, and a clear path to new approvals—making it a strong pick for investors focused on precision‑medicine innovation.

Jiangsu Hengrui Pharmaceuticals Co Ltd has secured a licensing agreement with Glenmark Specialty for the novel therapeutic agent SHR-A1811, a treatment for HER2-positive non-small cell lung cancer, which is expected to boost the company’s revenue an…

Jiangsu Hengrui Pharmaceuticals Co Ltd remains a strong and resilient player in the healthcare industry, driven by its commitment to innovation and strategic partnerships, despite recent market volatility.

Jiangsu Hengrui Pharmaceuticals, a Chinese healthcare giant, is experiencing unprecedented growth in innovative drug sales, with two of its medications, Revirulamin and Darzalex, driving a 60.66% share of its total revenue.

Jiangsu Hengrui Pharmaceuticals Co Ltd reported a 12% increase in quarterly revenue to a record 9.16 billion HKD, driven by its focus on innovative drug sales and international expansion.

Jiangsu Hengrui Pharmaceuticals has demonstrated resilience in the face of market volatility, thanks to its strong fundamentals and diversified product portfolio.

Jiangsu Hengrui Pharmaceuticals’ stock price has surged due to its innovative approach to medicine development, strategic partnerships, and favorable business environment in China and beyond.